Seroprevalence of HIV,hepatitis b,and hepatitis c among opioid drug users on methadone treatment in the netherlands |
| |
| Authors: | Imke Schreuder Marianne AB van der Sande Matty de Wit Monique Bongaerts Charles AB Boucher Esther A Croes Maaike G van Veen |
| |
| Affiliation: | (1) Department of Virology, Erasmus MC, Dr. Molewaterplein 50, Rotterdam, 3000, CA, the Netherlands;(2) Department of Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute of Public Health and Environment, Antonie van Leeuwenhoeklaan 9, Bilthoven, 3721, MA, the Netherlands;(3) Department of Epidemiology, Documentation and Health Promotion, Public Health Service, Nieuwe Achtergracht 100, Amsterdam, 1018, WT, the Netherlands;(4) Division Addiction Care Group, Mondriaan centre, Valkenburgerweg 17, Heerlen, 6411, BM, the Netherlands;(5) Department of Prevention, Trimbos-institute, Da Costakade 45, Utrecht, 3521, VS, the Netherlands;(6) Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht, 3508, GA, the Netherlands |
| |
| Abstract: | ![]()
Background Injecting drug users (IDU) remain an important population at risk for blood-borne infections such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV). In the Netherlands, a program is being implemented to offer annual voluntary screening for these infections to opioid drug users (ODUs) screened in methadone care. At two care sites where the program is now operating, our study aimed to estimate the seroprevalence among ODUs screened for HIV, HBV and HCV; to evaluate HBV vaccination coverage; and to assess the feasibility of monitoring seroprevalence trends by using routine annual screening data. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
